Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Lennon
NEOSTIGMINE METHYL SULPHATE INJECTION INTRAMED 0,5 mg/1 mL NEOSTIGMINE METHYL SULPHATE INJECTION INTRAMED 2,5 mg/1 mL NEOSTIGMINE METHYL SULPHATE INJECTION INTRAMED 2,5 mg/mL 5 mL vial SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): NEOSTIGMINE METHYL SULPHATE INJECTION INTRAMED 0,5 mg/1 mL NEOSTIGMINE METHYL SULPHATE INJECTION INTRAMED 2,5 mg/1 mL NEOSTIGMINE METHYL SULPHATE INJECTION INTRAMED 2,5 mg/mL 5 mL vial COMPOSITION: Each 1 mL contains 0,5 mg Neostigmine methyl sulphate Each 1 mL contains 2,5 mg Neostigmine methyl sulphate The vials contain 0,45% m/v phenol as preservative PHARMACOLOGICAL CLASSIFICATION; A5.3 Cholinomimetics (cholinergics) PHARMACOLOGICAL ACTION: Neostigmine is a reversible cholinesterase inhibitor. It is a quaternary ammonium compound and is absorbed poorly after oral administration. Neostigmine is destroyed by plasma esterases. The quaternary alcohol thus formed and the parent compound are excreted in the urine. INDICATIONS: – Atony of the smooth muscle of the gastro-intestinal tract: Paralytic ileus and abdominal distension; – Atony of the smooth muscle of the urinary bladder: Post operative dysuria; – Myasthenia gravis – The 2,5 mg/mL injection: Termination of the effects of competitive neuromuscular blocking agents such as d- tubocurarine and gallamine. CONTRA-INDICATIONS: Mechanical intestinal or urinary obstruction. In conjunction with depolarising muscle relaxants, such as suxamethonium. During cyclopropane or halothane anaesthesia, although it may be used after withdrawal of these agents. Patients with diabetes, gangrene or peritonitis. Pregnancy and lactation. WARNINGS: When Neostigmine Methylsulphate injection is used for myasthenia gravis; absence of clinical improvement may be indicative of overdosage or underdosage. Overdosage may lead to a Read the complete document